Cargando…
Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
PURPOSE: Fibroblast growth factor receptors (FGFR) and pathways are important players in breast cancer (BC) development. They are commonly altered, and BCs exhibiting FGFR gene amplification are currently being studied for drug development. Here, we aimed to compare the effects of three FGFR inhibit...
Autores principales: | Kähkönen, T. E., Toriseva, M., Petruk, N., Virta, A.-R., Maher, A., Eigéliené, N., Kaivola, J., Boström, P., Koskivuo, I., Nees, M., Tuomela, J. M., Ivaska, K. K., Härkönen, P. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907049/ https://www.ncbi.nlm.nih.gov/pubmed/33119860 http://dx.doi.org/10.1007/s13402-020-00562-0 |
Ejemplares similares
-
Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR-FGFR1 fusion
por: Qiu, Xu-Hua, et al.
Publicado: (2017) -
BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018) -
Hematopoietic stem cell regulatory volumes as revealed in studies of the bgj/bgj:W/WV chimera
Publicado: (1978) -
The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells
por: Na, Yu Ran, et al.
Publicado: (2021) -
Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
por: Boichuk, Sergei, et al.
Publicado: (2022)